Answers are grounded in this paper and cite their sources.
Latent tuberculosis infection (LTBI) is prevalent among patients with type 2 diabetes, and aryl hydrocarbon receptor (AhR) has been reported to be associated with LTBI. This observational study aimed to determine whether serum AhR levels decrease after tuberculosis prevention therapy (TPT). Patients with type 2 diabetes were enrolled for LTBI screening, and serum AhR levels were measured for those with a positive QuantiFERON-TB result. The patients received TPT, according to clinical practice: either weekly rifapentine plus isoniazid for 3 months (3HP) or daily isoniazid for 9 months (9H). Serum AhR levels were measured during a follow-up assessment at 36 weeks after enrollment in the patients who underwent continuous TPT for >3 months. Among 88 patients who completed the follow-up assessment, 47 (53.4%) received the 3HP regimen, and 41 (46.6%) received the 9H regimen. Serum AhR levels significantly decreased after TPT in the 3HP (45.4 [24.8, 55.44] to 13.4 [6.4, 23.8] pg/mL, p < 0.001) and 9H groups (43.4 [27.2, 60.8] to 14.6 [7.3, 21.3] pg/mL, p < 0.001). However, there was no statistically significant difference in the reduction in serum AhR levels between the 3HP and 9H groups (p = 0.286). In conclusion, serum AhR levels significantly decreased following TPT with the 3HP or 9H regimens.
No takes yet. Share an insight, caveat, or question.
Cheng et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: